LYR-210 Nasal Implant for CRS Brings Symptom Relief in Phase 3 ENLIGHTEN 2

Lyra Therapeutics Spikes 417% as LYR-210 Redefines CRS Therapy - Wall Street Pit

Lyra Therapeutics Inc. (LYRA) stock soared nearly 417% to $25.50, peaking at $37.50 intraday, after positive ENLIGHTEN 2 Phase 3 trial results for LYR-210, showing a significant 1.13-point improvement (p=0.0078) in CRS symptoms at week 24. LYR-210’s success in treating chronic rhinosinusitis without nasal polyps positions Lyra to advance its…

LYR-210 Nasal Implant for CRS Brings Symptom Relief in Phase 3 ENLIGHTEN 2

Lyra Therapeutics announced LYR-210 met primary and secondary endpoints in phase 3 ENLIGHTEN 2, improving CRS symptoms and showing strong safety.

Lyra Therapeutics Skyrockets: Premarket Surge to $30 Shocks Traders! – Own Snap

Lyra had a quite turbulent year in the markets. Today, it shocks everyone with stunning jump to $29.53, sparking a wave of trader interest! Lyra, a biotech player specializing in innovative treatments for ear, nose, and throat conditions, has seen its share price plummet since July of last year – from highs close to $32 down to a recent low of $4.93. That has been a rough ride. The chart reveals a bumpy trajectory: a prolonged downward trend thr…